Full Press Release Details
Pharmaceuticals to Present at the
Annual Growth Conference
VICTORIA, British Columbia--(BUSINESS WIRE)--August 6, 2015--Aurinia
Pharmaceuticals Inc., (NASDAQ: AUPH / TSX:AUP) today announced that its
Chief Operating Officer Michael R. Martin will present a corporate
overview of the company at the Canaccord Genuity 35th Annual
Growth Conference, taking place August 12-13 in Boston at the
Intercontinental Hotel.
Aurinia Presentation Details
Time: 9:30 a.m. Eastern
Location: InterContinental
Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is
currently in the recruitment and enrollment phase of its Phase 2b
clinical trial to evaluate the efficacy of its drug, voclosporin, as a
treatment for lupus nephritis (LN). LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com for more information.
Aurinia Pharmaceuticals Inc.
Zaruby, 250-708-4293
President & Chief Executive Officer
Michael R. Martin, 250-708-4272